Medical Oncology

EGFR+

Questions discussed in this category

Would you hold osimertinib in a patient with a STEMI, and for how long?

1 Answer available

Would you offer adjuvant chemotherapy, osimertinib, or both to a patient with Stage IB EGFR mutated lung adenocarcinoma found in the lung explant pathology after bilateral lung transplant?

Would you consider the immune suppressed status of the patient as a high risk factor to offer adjuvant therapy?

1 Answer available

Do you avoid immunotherapy in patients with Stage IV NSCLC with atypical EGFR mutations such as G719S or S768I?

1 Answer available

How do you approach EGFR mutated NSCLC with isolated progression in the chest who is planned for a course of radiation at least 3-4 weeks?

How do you balance the risk of an EGFR flare while holding osimertinib vs the risk of pneumonitis when continuing?

1 Answer available

How would you treat a patient with stage 4 NSCLC with EGFR R776H mutation?

2 Answers available

How many days do you hold osimertinib during or around SBRT for oligometastatic EGFR mutated advanced lung cancer?

Does the site of treatment factor into your decision?

2 Answers available

What is your approach to a patient with an EGFR exon 19 mutated NSCLC who develops progression on osimertinib and repeat biopsy demonstrates the EGFR exon 19 mutation and a new BRAF V600E mutation?

1 Answer available

In locally advanced EGFR-mutated NSCLC with initial good response to osimertinib, how do you manage local progression of the primary?

Would you consider SBRT and continue osimertinib?

2 Answers available

Should 3 years of adjuvant osimertinib be the standard of care for resected Stage IB-IIIA EGFRm NSCLC?

6 Answers available

Are there any safety or efficacy data regarding the use of EGFR inhibitors in patients on hemodialysis for ESRD?

1 Answer available

Are there any subsets of patients where you would consider first-line dacomitinib for EGFR mutations positive NSCLC?

Are there specific mutations or co-mutations were you would consider use of this agent?

1 Answer available

Would you offer EGFR inhibitors to a patient with metastatic lung adenocarcinoma EGFR L858R mutation and concomitant NRAS mutation both on blood based testing?

1 Answer available

How would you treat a patient with metastatic NSCLC >50% PDL-1 positive AND an EGFR or ALK gene mutation/rearrangement in the first-line setting?

1st-line pembrolizumab is supposed to be used AFTER failure of appropriate targeted agents in this setting, but would you consider the reverse sequenc...

2 Answers available

How do you approach a patient who responded to first line osimertinib but develop an isolated progressing lesion that retains sensitizing EGFR mutation but develops MET amplification?

Would you continue osimertinib after radiation therapy, switch to crizotinib, or consider chemotherapy +/- immunotherapy?

1 Answer available

Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?

The EGFR subgroup appeared not have benefited as much as other patients in the publication. However, recently it was reported that the PACIFIC study m...

1 Answer available

Do you use a TKI for resected EGFR+ non-small cell lung cancer?

In IB-IIIA cases?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2015-10-22

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2016-11-10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

J Thorac Oncol,

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

Clin. Cancer Res., 2015 May 27

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.

Lancet (London, England), 2017-01-21

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Lancet (London, England), 2016-04-09

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

The New England journal of medicine, 2018-06-14

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

The Lancet. Respiratory medicine, 2019-05

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Ann. Oncol.,

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

The New England journal of medicine, 2018-12-13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

J. Clin. Oncol., 2019 Dec 11

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).

Lancet Oncol., 2017 Sep 25

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-12-01

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

N Engl J Med, 2020 Sep 19

Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.

J Clin Oncol, 2020 Dec 04

Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics.

Clin Oncol (R Coll Radiol), 2017 Nov 16

Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-06

Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.

Radiother Oncol, 2020 Jul 31

An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib.

The Lancet. Oncology, 2015-07

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

J BUON,

Chromosome 7 deregulation in non-small cell lung carcinoma molecular landscape.

Br J Cancer, 2019 Sep 30

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Biochemistry, 2015 Jul 06

Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase.

N Engl J Med, 2019 Nov 21

Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.

Lancet Oncol, 2016 Apr 12

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-01

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

Future Oncol, 2018 Nov 08

Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing.

World J Clin Cases,

Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report.

Br J Cancer, 2016 Nov 22

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011-10-01

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).

Lung Cancer, 2020 Nov 13

Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.

Neuropathology, 2019 Mar 13

Rapidly progressive miliary brain metastasis of lung cancer after EGFR tyrosine kinase inhibitor discontinuation: An autopsy report.

Respir Investig, 2014 Nov 13

Disease flare after gefitinib discontinuation.

JACC CardioOncol, 2019 Dec 17

Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS).

J. Clin. Oncol., 2008-07-20

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

J Clin Oncol, 2021 Nov 02

Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With Mutation (IMPACT).

Related Topics in Medical Oncology